SEARCH RESULTS FOR: "Tag: GILD"
REFINE YOUR SEARCH:
RECENT
Last Month(1)
ARTICLES/BLOGS
2019(6)
2018(8)
2017(26)
2016(38)
2015(31)
2014(16)
CATEGORIES
5-Minute Market Rundown(1)
Analyst Downgrades(11)
Analyst Update(19)
Analyst Upgrades(8)
Best and Worst Stocks(1)
Buzz Stocks(10)
By the Numbers(3)
Earnings Preview(5)
Editor's Pick(1)
Expectational Analysis(2)
General(22)
Intraday Option Activity(13)
Market Recap(2)
Midday Market Check(1)
Most Active Options Update(2)
Most Active Weekly Options(2)
Opening View(12)
Quantitative Analysis(1)
Stock Market News(4)
Stocks On the Move(17)
Technical Analysis(1)
The Week Ahead(3)
Trader Content(1)

7/29/2019 9:13 AM
Shares of drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) are up 1.5% in pre-market trading, after the stock received an upgrade to "top pick" from "outperform" out of RBC. The brokerage firm cited new...
5/28/2019 9:27 AM
Goldman Sachs downgraded Gilead Sciences, Inc. (NASDAQ:GILD) to "sell" from "neutral," and slashed its price target by $10 to $60 -- a discount to last Friday's close at $66.89. The brokerage firm s...
3/29/2019 10:23 AM
Galapagos NV (NASDAQ:GLPG) and Gilead Sciences, Inc. (NASDAQ:GILD) stocks are higher this morning, after the companies reported positive data for a jointly developed drug to treat moderate-to-severe...
3/15/2019 9:40 AM
Brokerage firm BMO just began coverage on Amgen, Inc. (NASDAQ:AMGN) and Gilead Sciences, Inc. (NASDAQ:GILD), expecting major upside from both stocks. Let's take a closer look at the bull notes, alon...
2/12/2019 9:28 AM
The shares of Gilead Sciences, Inc. (NASDAQ:GILD) are down 3.1% in electronic trading, after the biotech said a late-stage trial for its Non-Alcoholic Steatohepatitis (NASH) drug, selonsertib, failed...

Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we've since become a trusted source of research and analysis for individual investors and major financial media outlets alike.







Partner Center